東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Biostatistics in biopharmaceutical r...

Chen, Ding-Geng.

FindBook

Google Book

Amazon

博客來

Biostatistics in biopharmaceutical research and development.. Volume 1,. Clinical trial design

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Biostatistics in biopharmaceutical research and development./ edited by Ding-Geng Chen.
其他題名:	Clinical trial design
其他作者:	Chen, Ding-Geng.
出版者:	Cham :Springer Nature Switzerland : : 2024.,
面頁冊數:	xxiv, 344 p. :ill., digital ;24 cm.
內容註:	Bias and Randomization in Clinical Trials: 1980s - 2020s - 2060s -- The Markov Model for Survival Trials at 35 Years-Old -- Absolute Power Corrupts Absolutely: A Review of the Use of Unconditional Probabilities in the Planning of Clinical Trials -- Design of Clinical Trials with the Desirability of Outcome Ranking Methodology -- Benefit:Risk Assessments during Clinical Trials: A Prediction Approach Using the Desirability of Outcome Ranking (DOOR) -- The Power of Integration: How the 2-in-1 Clinical Trial Design is Changing the Future of Drug Development -- A Unified Bayesian Decision Rule-Based Approach for Bayesian Design of Clinical Trials Using Historical Data -- Group Sequential Design Under Non-proportional Hazards: Methodologies and Examples -- Multiple Testing in Group Sequential Design -- Plan per-protocol (PP) causal inference analysis addressing intercurrent events following the targeted learning roadmap -- Maximum Tolerated Imbalance Randomization: Theory and Practice -- Response-adaptive randomization designs based on optimal allocation proportion.
Contained By:	Springer Nature eBook
標題:	Clinical trials - Design. -
電子資源:	https://doi.org/10.1007/978-3-031-65948-5
ISBN:	9783031659485

Biostatistics in biopharmaceutical research and development.. Volume 1,. Clinical trial design
Biostatistics in biopharmaceutical research and development.Volume 1,Clinical trial design[electronic resource] /Clinical trial designedited by Ding-Geng Chen. - Cham :Springer Nature Switzerland :2024. - xxiv, 344 p. :ill., digital ;24 cm.

Bias and Randomization in Clinical Trials: 1980s - 2020s - 2060s -- The Markov Model for Survival Trials at 35 Years-Old -- Absolute Power Corrupts Absolutely: A Review of the Use of Unconditional Probabilities in the Planning of Clinical Trials -- Design of Clinical Trials with the Desirability of Outcome Ranking Methodology -- Benefit:Risk Assessments during Clinical Trials: A Prediction Approach Using the Desirability of Outcome Ranking (DOOR) -- The Power of Integration: How the 2-in-1 Clinical Trial Design is Changing the Future of Drug Development -- A Unified Bayesian Decision Rule-Based Approach for Bayesian Design of Clinical Trials Using Historical Data -- Group Sequential Design Under Non-proportional Hazards: Methodologies and Examples -- Multiple Testing in Group Sequential Design -- Plan per-protocol (PP) causal inference analysis addressing intercurrent events following the targeted learning roadmap -- Maximum Tolerated Imbalance Randomization: Theory and Practice -- Response-adaptive randomization designs based on optimal allocation proportion.

The Deming Conference on Applied Statistics has long been deemed an influential event in the biostatistics and biopharmaceutical profession. It provides learning experience on recent developments in statistical methodologies in biopharmaceutical applications and FDA regulations. This book honors 80 years of contributions and dedication of the Deming Conference in biostatistics, and biopharmaceutical clinical trial methodology and applications. All chapters are contributed by world-class and prominent Deming speakers, who've contributed their cutting-edge research and developments to the community. Volume 1 covers Historical Milestones in Clinical Trial Design, FDA biopharmaceutical design guidance, and emerging development in Clinical Trial Design Methodology. This book aims to booster research, education, and training in biostatistics and in biopharmaceutical research and development.

ISBN: 9783031659485

Standard No.: 10.1007/978-3-031-65948-5doiSubjects--Topical Terms:

2184916
Clinical trials
--Design.

LC Class. No.: R853.C55

Dewey Class. No.: 615.50724

Biostatistics in biopharmaceutical research and development.. Volume 1,. Clinical trial design
LDR:03018nmm a2200337 a 4500 001 2389244
003 DE-He213
005 20241225115231.0
006 m d
007 cr nn 008maaau
008 250916s2024 sz s 0 eng d
020 $a 9783031659485 $q (electronic bk.)
020 $a 9783031659478 $q (paper)
024 7 $a 10.1007/978-3-031-65948-5 $2 doi
035 $a 978-3-031-65948-5
040 $a GP $c GP
041 0 $a eng
050 4 $a R853.C55
072 7 $a PBT $2 bicssc
072 7 $a MED090000 $2 bisacsh
072 7 $a PBT $2 thema
082 0 4 $a 615.50724 $2 23
090 $a R853.C55 $b B616 2024
245 0 0 $a Biostatistics in biopharmaceutical research and development. $n Volume 1, $p Clinical trial design $h [electronic resource] / $c edited by Ding-Geng Chen.
246 3 0 $a Clinical trial design
260 $a Cham : $b Springer Nature Switzerland : $b Imprint: Springer, $c 2024.
300 $a xxiv, 344 p. : $b ill., digital ; $c 24 cm.
505 0 $a Bias and Randomization in Clinical Trials: 1980s - 2020s - 2060s -- The Markov Model for Survival Trials at 35 Years-Old -- Absolute Power Corrupts Absolutely: A Review of the Use of Unconditional Probabilities in the Planning of Clinical Trials -- Design of Clinical Trials with the Desirability of Outcome Ranking Methodology -- Benefit:Risk Assessments during Clinical Trials: A Prediction Approach Using the Desirability of Outcome Ranking (DOOR) -- The Power of Integration: How the 2-in-1 Clinical Trial Design is Changing the Future of Drug Development -- A Unified Bayesian Decision Rule-Based Approach for Bayesian Design of Clinical Trials Using Historical Data -- Group Sequential Design Under Non-proportional Hazards: Methodologies and Examples -- Multiple Testing in Group Sequential Design -- Plan per-protocol (PP) causal inference analysis addressing intercurrent events following the targeted learning roadmap -- Maximum Tolerated Imbalance Randomization: Theory and Practice -- Response-adaptive randomization designs based on optimal allocation proportion.
520 $a The Deming Conference on Applied Statistics has long been deemed an influential event in the biostatistics and biopharmaceutical profession. It provides learning experience on recent developments in statistical methodologies in biopharmaceutical applications and FDA regulations. This book honors 80 years of contributions and dedication of the Deming Conference in biostatistics, and biopharmaceutical clinical trial methodology and applications. All chapters are contributed by world-class and prominent Deming speakers, who've contributed their cutting-edge research and developments to the community. Volume 1 covers Historical Milestones in Clinical Trial Design, FDA biopharmaceutical design guidance, and emerging development in Clinical Trial Design Methodology. This book aims to booster research, education, and training in biostatistics and in biopharmaceutical research and development.
650 0 $a Clinical trials $x Design. $3 2184916
650 0 $a Biometry. $3 531975
650 0 $a Biopharmaceutics. $3 690368
650 1 4 $a Biostatistics. $3 1002712
650 2 4 $a Clinical Research. $3 3531315
650 2 4 $a Public Health. $3 624351
650 2 4 $a Survey Methodology. $3 3602229
650 2 4 $a Data Mining and Knowledge Discovery. $3 898250
700 1 $a Chen, Ding-Geng. $3 1097388
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer Nature eBook
856 4 0 $u https://doi.org/10.1007/978-3-031-65948-5
950 $a Medicine (SpringerNature-11650)